NCT05721729View on ClinicalTrials.gov

Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

June 23, 2023

Primary Completion Date

May 1, 2024

Study Completion Date

May 1, 2025

Conditions

Postbariatric Hypoglycemia

Interventions

DRUG

Mizagliflozin

Encapsulated

DRUG

Placebo

Encapsulated

Trial Locations (2)

80045

University of Colorado / Anschutz Medical Campus, Aurora

94304

Stanford, Palo Alto

All Listed Sponsors

lead

Vogenx, Inc.

INDUSTRY